Approach to the treatment of multiple myeloma: a clash of philosophies

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

(2011) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple myeloma and the road to personalised medicine

(2011) Stephen J Russell et al.   LANCET ONCOLOGY

Treatment of multiple myeloma

(2011) S. Vincent Rajkumar   Nature Reviews Clinical Oncology

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

(2010) J.-L. Harousseau et al.   BLOOD

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

(2010) B. Nair et al.   BLOOD

Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

(2010) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

(2010) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences

(2010) Bart Barlogie et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

The role of complete response in multiple myeloma

(2009) J.-L. Harousseau et al.   BLOOD

A monoclonal gammopathy precedes multiple myeloma in most patients

(2009) B. M. Weiss et al.   BLOOD

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

The Importance of Complete Response in Outcomes in Myeloma

(2009) Ajay Nooka et al.   CANCER JOURNAL

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

(2009) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

The molecular characterization and clinical management of multiple myeloma in the post-genome era

(2009) Y Zhou et al.   LEUKEMIA

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Proteasome inhibitors in the treatment of multiple myeloma

(2009) J J Shah et al.   LEUKEMIA

Treatment of Myeloma: Cure vs Control

(2009) S. Vincent Rajkumar   MAYO CLINIC PROCEEDINGS

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

(2009) Shaji K. Kumar et al.   MAYO CLINIC PROCEEDINGS

A change of strategy in the war on cancer

(2009) Robert A. Gatenby   NATURE

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

(2008) H. Ludwig et al.   BLOOD

Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception

(2008) Leonard B. Saltz   JOURNAL OF CLINICAL ONCOLOGY

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reflections on Medical Oncology: 25 Years of Clinical Trials—Where Have We Come and Where Are We Going?

(2007) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY